Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Q2 FY27 Earnings Presentation
17 slides from Dr. Reddy's Laboratories's earnings presentation, Oct 23, 2026
Slide 1: Regulation 30 intimation cover letter to stock exchanges
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: [email protected] Web: www.drreddys.com October 23, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
Slide 2: Q2FY27 Results Update
Dr. Reddy’s Q2FY27 RESULTS UPDATE 23 OCTOBER 2026 1 | September 2025 | Investor Presentation | As per consolidated financial statements under IFRS
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 4: Q2FY27 Financial Highlights
Q2FY27 Financial Highlights Consistent double-digit base business^ growth, with EBITDA Margin @20.6% Reported Revenues ₹ 8,671 Cr 1.5% YoY 7% QoQ • Double-digit underlying base business^ YoY growth o Reported YoY growth declined 1.5% due to lower lenalidomide sales EBITDA | EBITDA % ₹ 1,783 Cr | 20.
Slide 5: Q2FY27 Business Highlights
Q2FY27 Business Highlights Steady progress across strategic priorities • Partnered with Takeda for India’s 1st Central Drugs Standard Control Organisation (CDSCO) approved dengue vaccine, QDENGA; to launch in private markets in H1 2027 • Expanded collaboration with Gilead Sciences for investigationa
Slide 6: Q2FY27 Other Highlights
Q2FY27 Other Highlights ESG • ‘Silver’ medal by FinanceAsia in ‘Best Large Cap Company in India’ category at Asia’s Best Companies 2026 • Improved CRISIL ESG Rating to 73/100 for FY26 from 66/100 in FY25 - only pharma company in leadership category OTHER UPDATES • On track to resolve issue associate
Slide 7: Q2FY27 Revenue Split
Q2FY27 Revenue Split Double-digit base business* growth across key businesses, except Europe and API REVENUE BY SEGMENT GLOBAL GENERICS SPLIT North America Europe GLOBAL GENERICS ₹ 2,489 Cr ₹ 1,393 Cr 90% 23%YoY 13%QoQ 1%YoY 3%QoQ Overall 16% ₹ 8,671 Cr 29% 1.5% 7% YoY QoQ PSAI 9.5% 21% India OTHERS
Slide 8: Key Financial Metrics
Key Financial Metrics Sustaining growth & profitability, while investing for the future REVENUES GROSS MARGINS SG&A R&D EBITDA MARGINS (₹ Cr) (% of Revenues) (% of Revenues) (% of Revenues) (% of Revenues) Q2FY27 8,671 Q2FY27 52.1% Q2FY27 32.4% Q2FY27 6.0% Q2FY27 20.6% Q1FY27 8,071 *Q1FY27 46.5% Q1F
Slide 9: North America Performance
Q2FY27 North America Performance Continued double digit growth in base business*; reported growth impacted by lower lenalidomide sales MARKET PERFORMANCE KEY UPDATES 29% 12.4% VS 2.1% • Double digit base business* growth in Q2FY27, aided DRL Growth vs US Generics Market (Excl. lenalidomide) *As per
Slide 10: Emerging Markets Performance
Q2FY27 Emerging Markets Performance Growth driven by new product launches across geographies, aided by favourable forex movements KEY UPDATES 24% COUNTRIES PRESENT IN • Secured approval for generic semaglutide in 8 emerging markets 50 across Latin America, Africa, and the Middle East till date NEW P
Slide 11: India Performance
Q2FY27 India Performance Moved up to #8 in IPM for the quarter, delivering consistent double-digit growth ahead of IPM MARKET PERFORMANCE* KEY UPDATES 21% 21.0% VS 14.7% *DRL MQT Growth vs IPM (Sep’26) • Partnered with Takeda for India’s 1st CDSCO approved dengue vaccine, QDENGA; launch planned in p
Slide 12: Europe Performance
Q2FY27 Europe Performance Generics launch momentum & forex gains, partly offset by pricing pressure & NRT operating model changes 16% KEY UPDATES EU* COUNTRIES PRESENT IN • As reported in Q1FY27, NRT growth impacted by post-integration operating 21 model changes; change is profit neutral *Excludes N
Slide 13: PSAI Performance
Q2FY27 PSAI Performance Lower API volume offtake impacting growth; CDMO business scales to $100 mn in annualized revenues KEY UPDATES 9.5% GROSS MARGIN • Expanded collaboration with Gilead Sciences for investigational once- yearly lenacapavir for HIV prevention in 120 countries, including India 11.8
Slide 14: In Summary
In Summary A diversified business model with broad based levers Strengthen Core Businesses, build future growth drivers (Peptides, Biosimilars, Consumer Health, Innovative Assets) Advance key products (Semaglutide including re-launch, Abatacept) Drive efficiencies through better operational leverage
Slide 15: At a glance
At a glance We accelerate access to affordable and innovative medicines because Good Health Can’t Wait. ~699mn patients reached globally $3.6bn Revenue ~23% EBITDA Margin ~16% RoCE 27,500+ Employees globally 64 Nationalities (Employees) 88 Markets served 33 Plants (Manufacturing & R&D) Sales and Oth
Slide 16: About Key Metrics and Non-GAAP Financial Measures
About Key Metrics and Non-GAAP Financial Measures This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non- GAAP financial measures are measures of our historical performance, financial position or cash flows that are
Slide 17: Good Health Can't Wait.
Good Health Can’t Wait. 16 | September 2025 | Investor Presentation | As per consolidated financial statements under IFRS
Dr. Reddy's Laboratories — Q2 FY27 Earnings Presentation on 6ix